Medicare Enrolled

Dr. Eric Kleinbaum, M.D.

Hematology & Oncology · Houston, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
17323 RED OAK DR, Houston, TX 77090
2814405006
In practice since 2006 (19 years)
NPI: 1932140159 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Kleinbaum from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kleinbaum? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Kleinbaum

Dr. Eric Kleinbaum is a hematology & oncology in Houston, TX, with 19 years in practice. Based on federal Medicare data, Dr. Kleinbaum performed 114,931 Medicare services across 1,784 unique beneficiaries.

Between the years covered by Open Payments, Dr. Kleinbaum received a total of $6,138 from 60 pharmaceutical and/or device companies across 331 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Kleinbaum is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 5% volume in TX$ $6,138 industry payments

Medicare Practice Summary

Medicare Utilization ↗
114,931
Medicare services
Top 5% in TX for hematology & oncology
1,784
Unique beneficiaries
$3
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~6,049 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Iron infusion (Injectafer)72,000$1$3
Contrast dye for imaging (iodine-based)17,900$0$0
Anti-nausea injection (fosaprepitant)9,750$0$1
MRI contrast dye injection (gadoterate)7,250$0$0
Dexamethasone injection (steroid)2,174$0$0
Anti-nausea injection (Aloxi/palonosetron)1,240$1$5
Office visit, established patient (30-39 min)1,124$91$346
Flow cytometry, additional marker625$19$63
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less607$22$82
Administration of chemotherapy into vein, 1 hour or less331$96$375
Office visit, established patient (20-29 min)311$62$245
Drug injection, under skin or into muscle161$10$38
Administration of chemotherapy into vein, each additional hour156$21$80
Ct scan of chest with contrast143$54$428
Administration of additional new drug or substance into vein, 1 hour or less129$49$183
CT scan of abdomen and pelvis with contrast126$163$812
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less119$46$179
New patient office visit (45-59 min)106$116$452
Irrigation of implanted venous access drug delivery device85$18$73
Injection, diphenhydramine hcl, up to 50 mg68$1$3
Hospital follow-up visit, moderate complexity65$56$200
Infusion into a vein for hydration, each additional hour57$10$36
Nuclear medicine study from skull base to mid-thigh with ct scan47$1,132$5,457
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries43$109$295
Ct scan of soft tissue of neck with contrast38$59$443
Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional36$17$62
Complete ultrasound scan of abdomen35$54$278
Hospital follow-up visit, high complexity33$89$297
Mri scan of brain before and after contrast26$138$863
Flow cytometry technique for dna or cell analysis, first marker25$60$194
CT scan of chest, without contrast22$34$335
Biopsy and aspiration of bone marrow sample for diagnosis21$133$479
Office visit, established patient (10-19 min)18$43$156
Ct scan of abdomen and pelvis without contrast17$62$467
Mri scan of abdomen before and after contrast17$191$915
Initial hospital admission, moderate complexity14$100$355
New patient office visit (30-44 min)12$59$300
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
63.3% high complexity
34.4% medium
2.3% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$6,138
Total received (2018-2024)
Avg $877/year across 7 years
Top 40% in TX for hematology & oncology
60
Companies
331
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,855 (95.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$283 (4.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$349
2023
$952
2022
$760
2021
$509
2020
$335
2019
$786
2018
$2,446

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$607
Novartis Pharmaceuticals Corporation
$457
E.R. Squibb & Sons, L.L.C.
$362
Janssen Biotech, Inc.
$330
Eisai Inc.
$318
Amgen Inc.
$317
Astellas Pharma US Inc
$270
Merck Sharp & Dohme Corporation
$243
EISAI INC.
$208
Lilly USA, LLC
$191
Gilead Sciences, Inc.
$165
GENZYME CORPORATION
$155
AstraZeneca Pharmaceuticals LP
$140
Celgene Corporation
$138
Pharmacyclics LLC, An AbbVie Company
$128
Incyte Corporation
$126
Daiichi Sankyo Inc.
$106
Puma Biotechnology, Inc.
$104
ARRAY BIOPHARMA INC
$102
Takeda Pharmaceuticals U.S.A., Inc.
$97
PUMA BIOTECHNOLOGY, INC.
$97
BeiGene USA, Inc.
$93
GlaxoSmithKline, LLC.
$83
Foundation Medicine, Inc.
$81
TESARO, Inc.
$74
Janssen Pharmaceuticals, Inc
$73
SANOFI-AVENTIS U.S. LLC
$72
CTI BioPharma Corp.
$71
Sirtex Medical Inc
$68
Spectrum Pharmaceuticals Inc.
$60
Genentech USA, Inc.
$57
Exelixis Inc.
$54
Boehringer Ingelheim Pharmaceuticals, Inc.
$52
Bayer Healthcare Pharmaceuticals Inc.
$46
Bayer HealthCare Pharmaceuticals Inc.
$45
Rigel Pharmaceuticals, Inc.
$43
AbbVie Inc.
$38
Dendreon Pharmaceuticals LLC
$37
Teva Pharmaceuticals USA, Inc.
$32
Immunomedics, Inc.
$28
Clovis Oncology, Inc.
$26
BOSTON SCIENTIFIC CORPORATION
$25
Pharmacosmos Therapeutics Inc.
$25
AVEO Pharmaceuticals, Inc.
$24
Regeneron Healthcare Solutions, Inc.
$22
Aveo Pharmaceuticals, Inc.
$20
Emmaus Medical, Inc.
$20
Karyopharm Therapeutics Inc.
$19
SpringWorks Therapeutics, Inc.
$18
Ipsen Biopharmaceuticals, Inc
$18
MorphoSys, US Inc.
$18
Agios Pharmaceuticals, Inc.
$18
Mirati Therapeutics, Inc.
$17
Otsuka America Pharmaceutical, Inc.
$17
ABBVIE INC.
$17
Covidien LP
$16
Taiho Oncology, Inc.
$14
Heron Therapeutics, Inc.
$14
Acrotech Biopharma LLC
$12
Blueprint Medicines Corporation
$11
Top 3 companies account for 23.2% of total payments
Associated products mentioned in payments ›
ALIMTA · AVYCAZ · Abraxane · Avastin · BELEODAQ · BENDEKA · BOSULIF · BRAFTOVI · BRUKINSA · CABLIVI · CHANTIX · CINVANTI · CREON · CYRAMZA · Cabometyx · DARZALEX · ELIQUIS · EMEND · EMPLICITI · ENJAYMO · Endari · Enhertu · Erleada · FOTIVDA · FOUNDATIONONE · Fabhalta · Folotyn · GAVRETO · GILOTRIF · General - Vascular Access · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LORBRENA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OGSIVEO · OJJAARA · OPDIVO · PADCEV · PROMACTA · PROVENGE · Perjeta · Pomalyst · Prolia · REBLOZYL · RETEVMO · RYDAPT · Revlimid · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SIMPONI ARIA · SIR-Spheres Microspheres · SPRYCEL · SUTENT · Somatuline Depot · Stivarga · SuperDimension · TAGRISSO · TECENTRIQ · Tavalisse · Trodelvy · VENCLEXTA · VERZENIO · VOTRIENT · Vectibix · Vonjo · XALKORI · XARELTO · XPOVIO · XTANDI · Xospata · Xtandi · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (95%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $5 per 100 Medicare services performed
Looking for a hematology & oncology in Houston?
Compare hematology & oncologys in the Houston area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncologys nearby

Geographic Context

Hematology & Oncologys within 10 mi
203
Per 100K population
4.3
County median income
$73,104
Nearest hospital
HCA HOUSTON HEALTHCARE NORTHWEST
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Kleinbaum is a mixed practice specialist, with above-average Medicare volume (top 5% in TX), and low-engagement industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Kleinbaum experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Kleinbaum performed 72,000 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kleinbaum receive payments from pharmaceutical companies?
Yes. Dr. Kleinbaum received a total of $6,138 from 60 companies across 331 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kleinbaum's costs compare to other hematology & oncologys in Houston?
Dr. Kleinbaum's average Medicare payment per service is $3. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kleinbaum) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →